The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: May 24, 2022

Recently, in the field of cancer treatment, paradigm has changed to immunotherapy that activates immune system induce attacks. Among them, checkpoint inhibitors (ICI) are attracting attention as excellent and continuous clinical results. However, it shows not only limitations such efficacy some patients or indications, but also side-effects resistance occur. Therefore, is necessary understand factors tumor microenvironment (TME) affect immunotherapy, is, mechanism by which grows while evading suppressing attacks from within TME. Tumors can evade through various mechanisms restricting antigen recognition, inhibiting system, inducing T cell exhaustion. In addition, tumors inhibit accumulating specific metabolites signal TME limiting nutrients available cells. order overcome develop effective treatments therapeutic strategies, an approach needed functions cells integrated manner based on this review, we will examine effects cells, especially how anti-cancer strategies

Language: Английский

---

Targeting glutamine metabolism as a therapeutic strategy for cancer

Experimental & Molecular Medicine, Journal Year: 2023, Volume and Issue: 55(4), P. 706 - 715

Published: April 3, 2023

Abstract Proliferating cancer cells rely largely on glutamine for survival and proliferation. Glutamine serves as a carbon source the synthesis of lipids metabolites via TCA cycle, well nitrogen amino acid nucleotide synthesis. To date, many studies have explored role metabolism in cancer, thereby providing scientific rationale targeting treatment. In this review, we summarize mechanism(s) involved at each step metabolism, from transporters to redox homeostasis, highlight areas that can be exploited clinical Furthermore, discuss mechanisms underlying cell resistance agents target strategies overcoming these mechanisms. Finally, effects blockade tumor microenvironment explore maximize utility blockers

Language: Английский

---

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(1), P. 115 - 126

Published: Jan. 1, 2023

Language: Английский

---

Disulfidptosis: a new target for metabolic cancer therapy

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: April 27, 2023

Abstract Altered metabolism is a hallmark of cancer and presents vulnerability that can be exploited in treatment. Regulated cell death (RCD) plays crucial role metabolic therapy. A recent study has identified new metabolic-related RCD known as disulfidptosis. Preclinical findings suggest therapy using glucose transporter (GLUT) inhibitors trigger disulfidptosis inhibit growth. In this review, we summarize the specific mechanisms underlying outline potential future research directions. We also discuss challenges may arise clinical translation research.

Language: Английский

---

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: May 20, 2024

Abstract Tumor biomarkers, the substances which are produced by tumors or body’s responses to during tumorigenesis and progression, have been demonstrated possess critical encouraging value in screening early diagnosis, prognosis prediction, recurrence detection, therapeutic efficacy monitoring of cancers. Over past decades, continuous progress has made exploring discovering novel, sensitive, specific, accurate tumor significantly promoted personalized medicine improved outcomes cancer patients, especially advances molecular biology technologies developed for detection biomarkers. Herein, we summarize discovery development including history conventional innovative used biomarker classification biomarkers based on tissue origins, application clinical management. In particular, highlight recent advancements biomarker-based anticancer-targeted therapies emerging as breakthroughs promising strategies. We also discuss limitations challenges that need be addressed provide insights perspectives turn into opportunities this field. Collectively, multiple emphasized review may guidance precision medicine, broaden horizons future research directions, expedite patients according their rather than organs origin.

Language: Английский

---

Modulating Glycolysis to Improve Cancer Therapy

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2606 - 2606

Published: Jan. 30, 2023

Cancer cells undergo metabolic reprogramming and switch to a ‘glycolysis-dominant’ profile promote their survival meet requirements for energy macromolecules. This phenomenon, also known as the ‘Warburg effect,’ provides advantage cancer make tumor environment more pro-cancerous. Additionally, increased glycolytic dependence promotes chemo/radio resistance. A similar is shown by immune in microenvironment, inducing competition between tumor-infiltrating over nutrients. Several recent studies have that targeting enhanced glycolysis promising strategy them susceptible treatment with other conventional modalities, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, photodynamic therapy. Although several strategies been developed of are different stages pre-clinical clinical evaluation, there still lack effective specifically target cell improve efficacy. Herein, we reviewed our current understanding role how this phenomenon could be potential efficacy

Language: Английский

---

What is cancer metabolism?

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1670 - 1688

Published: Feb. 28, 2023

Language: Английский

---

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2652 - 2652

Published: Jan. 31, 2023

Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related deaths in world. Metabolic reprogramming considered a new hallmark cancer, but it remains unclearly described HCC. The dysregulation PI3K/AKT/mTOR signaling pathway common HCC and is, therefore, topic further research concern developing novel target for liver cancer therapy. In this review, we illustrate mechanisms by which network accountable regulating cellular metabolism, including glucose lipid amino acid pyrimidine oxidative summarize ongoing clinical trials based on inhibition

Language: Английский

---

Signaling pathways in cancer metabolism: mechanisms and therapeutic targets

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: May 10, 2023

Abstract A wide spectrum of metabolites (mainly, the three major nutrients and their derivatives) can be sensed by specific sensors, then trigger a series signal transduction pathways affect expression levels genes in epigenetics, which is called metabolite sensing. Life body regulates metabolism, immunity, inflammation sensing, coordinating pathophysiology host to achieve balance with external environment. Metabolic reprogramming cancers cause different phenotypic characteristics cancer cell from normal cell, including proliferation, migration, invasion, angiogenesis, etc. disorders cells further create microenvironment many kinds oncometabolites that are conducive growth cancer, thus forming vicious circle. At same time, exogenous also biological behavior tumors. Here, we discuss sensing mechanisms derivatives, as well abnormalities development various cancers, potential therapeutic targets based on metabolite-sensing signaling prevent progression cancer.

Language: Английский

---

Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: July 18, 2022

Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cells response to therapy-induced hostile environment are largely unknown. As central organelle for cellular energy supply, mitochondria can rapidly undergo dynamic changes integrate signaling pathways provide bioenergetic biosynthetic flexibility cells, which contributes multiple aspects tumor characteristics, including drug resistance. Therefore, targeting therapy overcoming has attracted increasing attention various types cancer. Multiple mitochondrial processes, dynamics, metabolism, apoptotic regulatory machinery, have been demonstrated be potential targets. However, recent insights into revealed complexity structure functions, elusive functions biology, inaccessibility mitochondria, posed challenges clinical application mitochondrial-based therapeutic strategies. discovery both novel mitochondria-targeting agents innovative approaches is urgently required. Here, we review most literature summarize molecular their intricate connection with In addition, an overview emerging strategies target effectively chemoresistance highlighted, emphasis on repositioning delivery approaches, may accelerate compounds therapy.

Language: Английский

---